OXFORD BIOMEDICA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 228.5 GBX | +3.86% |
|
+12.56% | +3.86% |
| Apr. 18 | Stifel Upgrades Oxford BioMedica to Buy from Hold, Lifts PT | MT |
| Apr. 18 | HSBC likes Haleon, cuts Flutter to 'hold' | AN |
| Sales 2023 * | 90.47M 113M | Sales 2024 * | 130M 162M | Capitalization | 229M 285M |
|---|---|---|---|---|---|
| Net income 2023 * | -89M -111M | Net income 2024 * | -38M -47.47M | EV / Sales 2023 * | 1.98 x |
| Net cash position 2023 * | 49.23M 61.49M | Net cash position 2024 * | 15.5M 19.36M | EV / Sales 2024 * | 1.64 x |
| P/E ratio 2023 * |
-2.51
x | P/E ratio 2024 * |
-5.94
x | Employees | 891 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 80.81% |
More Fundamentals
* Assessed data
More news
Latest transcript on Oxford Biomedica plc
More press releases
More news
| 1 day | +3.86% | ||
| 1 week | +12.56% | ||
| Current month | +13.68% | ||
| 1 month | +17.42% | ||
| 3 months | +26.80% | ||
| 6 months | +7.28% | ||
| Current year | +3.86% |
1 week
203.20
234.00
1 month
187.83234.00
Current year
167.00234.00
1 year
164.29474.50
3 years
164.291 678.00
5 years
164.291 678.00
10 years
88.701 678.00
| Managers | Title | Age | Since |
|---|---|---|---|
Frank Mathias
CEO | Chief Executive Officer | 62 | 23-03-26 |
Stuart Paynter
DFI | Director of Finance/CFO | 52 | 17-08-28 |
| Chairman | 68 | 20-06-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leone Patterson
BRD | Director/Board Member | 61 | 23-04-30 |
| Chairman | 68 | 20-06-23 | |
Stuart Henderson
BRD | Director/Board Member | 66 | 16-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 2 M€ | -.--% | ||
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 228.5 | +3.86% | 298,641 |
| 24-04-25 | 220 | +0.69% | 221,132 |
| 24-04-24 | 218.5 | +1.63% | 275,918 |
| 24-04-23 | 215 | +1.18% | 691,486 |
| 24-04-22 | 212.5 | +4.68% | 643,496 |
Delayed Quote London S.E., April 26, 2024 at 11:35 am EDT
More quotes
Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.
Calendar
2024-04-29
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
2.285
GBP
Average target price
3.963
GBP
Spread / Average Target
+73.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.86% | 285M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- OXB Stock
